Evidence map›Paper›PMID 21733508›Full record

Trial reportFertility and sterility2011

Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.

Paulina A Essah, James A Arrowood, Kai I Cheang, Swati S Adawadkar, Dale W Stovall, John E Nestler

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Fertility and sterility, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00682890 (Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome), which is not on this map. Cited by 16 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 5 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00682890 phase4terminatednot on this map

Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)

TypeinterventionalSponsorVirginia Commonwealth UniversityRan2005 to 2010Enrolled28ConditionsPolycystic Ovary Syndrome, PCOS, Insulin SensitivityArmsplacebo, metformin
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 5 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Paulina A EssahDepartment of Internal Medicine, School of Medicine, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, Virginia, USA. paessah@comcast.net
James A Arrowood
Kai I Cheang
Swati S Adawadkar
Dale W Stovall
John E Nestler
Virginia Commonwealth University Medical Center · USUniversity of Virginia · US

Funding

X-LINKED HYPOPHOSPHATEMIAM01RR000065 · NCRR · VIRGINIA COMMONWEALTH UNIVERSITY · PI CLORE, JOHN N. · 1985 to 2010
$24.8M
POLYCYSTIC OVARY SYNDROME: ROLE OF INSULIN RESISTANCEK24HD040237 · NICHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI NESTLER, JOHN E · 2001 to 2009
$887k
Insulin and the Polycystic Ovary SyndromeK23HD049454 · NICHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHEANG, KAI I · 2006 to 2010
$633k
Combination metformin and oral contraceptive for PCOSR03HD047298 · NICHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI ESSAH, PAULINA A · 2005 to 2006
$147k
NCRR NIH HHS M01 RR000065NCRR NIH HHS M01-RR00065NICHD NIH HHS K23 HD049454NICHD NIH HHS K23HD049454NICHD NIH HHS K24 HD040237NICHD NIH HHS K24HD40237NICHD NIH HHS R03 HD047298NICHD NIH HHS R03HD047298
6 · The paper itself

Abstract

In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10). After 3 months, both treatments had similar effects on androgen levels, lipid profile, insulin sensitivity, and serum inflammatory markers, but flow-mediated dilatation increased by 69.0% in the metformin plus OC group while it remained unchanged in the OC group. CLINICAL TRIAL REGISTRATION NO: NCT00682890.

Indexed as

Analysis of VarianceBiomarkersBlood GlucoseContraceptives, Oral, CombinedContraceptives, Oral, HormonalDouble-Blind MethodDrug CombinationsDrug Therapy, CombinationEndothelium, VascularEthinyl EstradiolFemaleGonadal Steroid HormonesHumansHypoglycemic AgentsInflammation MediatorsInsulinBiomarkersBlood GlucoseContraceptives, Oral, CombinedContraceptives, Oral, HormonalDrug CombinationsEthinyl EstradiolGonadal Steroid HormonesHypoglycemic AgentsInflammation MediatorsInsulinLipidsMetforminnorgestimate, ethinyl estradiol drug combinationNorgestrel

Identifiers

PMID21733508
PMCPMC4480914
OpenAlexW2049658225

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.